.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="52147988aad25537e9f800114ab7964f"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="52147988aad25537e9f800114ab7964f"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="52147988aad25537e9f800114ab7964f"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="52147988aad25537e9f800114ab7964f"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .wpv-view-output[data-toolset-views-view-editor="52147988aad25537e9f800114ab7964f"] .tb-masonry { grid-template-columns: minmax(0, 1fr) minmax(0, 1fr) minmax(0, 1fr);grid-column-gap: 5px; } .wpv-view-output[data-toolset-views-view-editor="52147988aad25537e9f800114ab7964f"] .tb-masonry .tb-brick__content { padding: 0 0 5px 0; } .wpv-pagination-nav-links[data-toolset-views-view-pagination-block="cdfd4c4737b2898eba4443dd59a1bf50"] { text-align: left;justify-content: flex-start; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="4c948d77db89a61a946e678c9a5e06f0"] { border-radius: 4px;padding: 25px;border: 1px solid rgba( 220, 220, 220, 1 ); } .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-button[data-toolset-blocks-button="ab32c16caf8370efbd491b67650c5ef9"] { text-align: right; } .tb-button[data-toolset-blocks-button="ab32c16caf8370efbd491b67650c5ef9"] .tb-button__link { background-color: rgba( 207, 46, 46, 1 );color: rgba( 255, 255, 255, 1 );padding: 5px 10px 5px 10px;font-size: 12px;color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="ab32c16caf8370efbd491b67650c5ef9"] .tb-button__icon { font-family: dashicons; } h3.tb-heading[data-toolset-blocks-heading="6a034f0d7cbdc49152b2ad0f8766f7c7"]  { text-align: left; }  .tb-image{position:relative;transition:transform 0.25s ease}.wp-block-image .tb-image.aligncenter{margin-left:auto;margin-right:auto}.tb-image img{max-width:100%;height:auto;width:auto;transition:transform 0.25s ease}.tb-image .tb-image-caption-fit-to-image{display:table}.tb-image .tb-image-caption-fit-to-image .tb-image-caption{display:table-caption;caption-side:bottom} .wp-block-image.tb-image[data-toolset-blocks-image="1665af3899fb0d862673ddf2eaf6d692"] { max-width: 100%; }   .tb-field[data-toolset-blocks-field="90dcf57a0bbb2db3ae5fcf10dfabbfbd"] { text-align: left; }  .tb-field[data-toolset-blocks-field="90dcf57a0bbb2db3ae5fcf10dfabbfbd"] a { color: rgba( 0, 0, 0, 1 ); } .tb-field[data-toolset-blocks-field="90dcf57a0bbb2db3ae5fcf10dfabbfbd"] a:hover { color: rgba( 207, 46, 46, 1 ); }  @media only screen and (max-width: 781px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="52147988aad25537e9f800114ab7964f"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="52147988aad25537e9f800114ab7964f"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="52147988aad25537e9f800114ab7964f"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="52147988aad25537e9f800114ab7964f"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .wpv-view-output[data-toolset-views-view-editor="52147988aad25537e9f800114ab7964f"] .tb-masonry { grid-template-columns: minmax(0, 1fr) minmax(0, 1fr) minmax(0, 1fr);grid-column-gap: 5px; } .wpv-view-output[data-toolset-views-view-editor="52147988aad25537e9f800114ab7964f"] .tb-masonry .tb-brick__content { padding: 0 0 5px 0; } .tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-image{position:relative;transition:transform 0.25s ease}.wp-block-image .tb-image.aligncenter{margin-left:auto;margin-right:auto}.tb-image img{max-width:100%;height:auto;width:auto;transition:transform 0.25s ease}.tb-image .tb-image-caption-fit-to-image{display:table}.tb-image .tb-image-caption-fit-to-image .tb-image-caption{display:table-caption;caption-side:bottom}     } @media only screen and (max-width: 599px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="52147988aad25537e9f800114ab7964f"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="52147988aad25537e9f800114ab7964f"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .wpv-view-output[data-toolset-views-view-editor="52147988aad25537e9f800114ab7964f"] .tb-masonry { grid-template-columns: minmax(0, 1fr) minmax(0, 1fr) minmax(0, 1fr);grid-column-gap: 5px; } .wpv-view-output[data-toolset-views-view-editor="52147988aad25537e9f800114ab7964f"] .tb-masonry .tb-brick__content { padding: 0 0 5px 0; } .tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-image{position:relative;transition:transform 0.25s ease}.wp-block-image .tb-image.aligncenter{margin-left:auto;margin-right:auto}.tb-image img{max-width:100%;height:auto;width:auto;transition:transform 0.25s ease}.tb-image .tb-image-caption-fit-to-image{display:table}.tb-image .tb-image-caption-fit-to-image .tb-image-caption{display:table-caption;caption-side:bottom}     } 

Medpace

CRO (Contract Research Organization)

🔗 Website

Medpace is a global research-based drug development company led by top scientists and regulatory experts who are driven to further the advancement of pharmaceuticals in the areas of cardiology, metabolism, and oncology.
With an unparalleled commitment to ‘best in class’ science, Medpace has assembled one of the industry’s most experienced and specialized medical teams to oversee every level of the company’s clinical operations, providing complete and seamless drug development services.

With 140 European associates, more than 700 additional employees worldwide, and clinical trial experience in 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide.
Through its specialized scientific and regulatory expertise and medically focused clinical operations, Medpace provides the pharmaceutical and biotechnology industries with the most efficient and cost-effective path to drug approval – from program development to product approval.

Imagepace
Imagepace is an industry leader in designing and executing clinical trials utilizing the most advanced imaging and biomarker technologies. Imagepace helps sponsors utilize advanced imaging technologies in clinical trial programs with a consistent, end-to-end suite of image acquisition, collection and analysis services as well as to champion the use of imaging to enhance and expedite drug development.

Medpace Bioanalytical Laboratories
Medpace Bioanalytical Laboratories provide comprehensive clinical development services in areas such as method transfer, development, validation, and analysis of pre-clinical and clinical biological samples utilizing state-of-the-art instrumentation.

Medpace Clinical Pharmacology
The Medpace Clinical Pharmacology Unit is a state-of-the-art Phase I, IIa facility with a core ECG lab focusing on confined/ controlled pharmacokinetic/ pharmacodynamic studies utilizing human volunteers, with first-in-man capability.

Medpace Reference Laboratories
Medpace Reference Laboratories is a central laboratory with locations in Cincinnati, Ohio; Leuven, Belgium; Mumbai, India; and Beijing, China. Expertise includes coagulation, cardiovascular diseases, oncology, lipids, diabetes, and other metabolic diseases. MRL offers analytical support during all stages of the drug development process, with an average of 30,000 square feet at each of the four locations dedicated to laboratory operations and specimen storage.

Medpace Medical Consulting
Medpace Medical Consulting is a highly regarded consultancy with long standing working relationships with multiple European regulatory authorities with particular expertise in European regulatory, pharmacovigilance, and safety, providing seamless trial integration in Europe in all aspects of regulatory approvals and submissions.

Medpace Medical Device
Medpace Medical Device is a global leader in execution of device trials, building strong strategic partnerships with select Sponsors to support the most efficient and cost-effective path to regulatory approval (e.g., 510 clearance, PMA, or CE mark), driving market adoption through well-designed and well-executed post-market outcomes or post-approval trials.